What are the possible causes of a conversion from a negative to a positive Tuberculin Gamma Interferon Release Assay (Quantiferon) test result?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

A change from a negative to positive QuantiFERON-TB Gold test (IGRA) indicates you have likely been infected with tuberculosis (TB) bacteria since your last test, and you should contact your healthcare provider immediately for evaluation. This conversion could be due to recent TB exposure, progression from a previously undetectable infection, or immune system changes allowing detection of an existing infection 1. False positives can occur from laboratory error, cross-reactivity with non-tuberculous mycobacteria, or recent BCG vaccination, though the latter is less common with QuantiFERON tests than with skin tests.

Possible Causes of Conversion

  • Recent TB exposure: This is a high-risk scenario, especially if you have been in close contact with someone with active TB disease 1.
  • Progression from a previously undetectable infection: This could be due to changes in your immune system or the progression of the infection itself.
  • Immune system changes: Certain medical conditions or treatments can affect your immune system, making it more likely to detect an existing infection.

Next Steps

You should undergo a medical evaluation, which typically includes:

  • A chest X-ray to rule out active TB disease
  • A physical examination and medical history to identify any risk factors or symptoms
  • Bacteriologic studies and serology for human immunodeficiency virus (HIV) if indicated 1 If active TB is excluded, you may be diagnosed with latent TB infection (LTBI) and offered preventive treatment, usually isoniazid (300mg daily for adults) for 6-9 months, rifampin (600mg daily for adults) for 4 months, or a 3-month regimen of weekly isoniazid plus rifapentine. Treatment reduces your risk of developing active TB disease by 60-90% 1.

Important Considerations

  • The decision to treat depends on your risk factors, including immune status, age, and potential exposure history.
  • Certain groups, such as close contacts of persons with infectious pulmonary TB, persons who have immigrated from areas with high rates of TB, and children under 5 years old, are at higher risk for recent TB infection and progression to active disease 1.

From the Research

Possible Causes of Reversion in QuantiFERON Test Results

The reversion from a negative to a positive QuantiFERON test result can be attributed to several factors. Some possible causes include:

  • Recent exposure to tuberculosis (TB) 2
  • Waning immunity over time, leading to a reactivation of latent TB infection 2
  • Variability in test results due to factors such as the timing of the test, the individual's immune response, and the presence of other infections 2

Risk Factors for Reversion

Certain risk factors can increase the likelihood of reversion in QuantiFERON test results. These include:

  • Younger age 2
  • Female sex 2
  • Lower baseline QuantiFERON test results (<0.738 IU/mL) 2

Treatment and Prevention of Latent TB Infection

Treatment of latent TB infection (LTBI) is crucial in preventing the progression to active TB disease. Various treatment regimens are available, including:

  • Isoniazid monotherapy for 6-9 months 3, 4, 5, 6
  • Rifampin-based regimens, such as once-weekly isoniazid and rifapentine for 12 weeks 3, 4, 5, 6
  • Four months of rifampin, which has been shown to be effective and does not require directly observed therapy (DOT) 6

Serial Testing and LTBI Treatment

Serial testing without LTBI treatment may be indicated in certain individuals, such as those who are female, younger, and have lower QuantiFERON test results 2. However, the decision to treat or not treat LTBI should be made on a case-by-case basis, taking into account individual risk factors and medical history.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Frequency of and risk factors for reversion of QuantiFERON test in healthcare workers in an intermediate-tuberculosis-burden country.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2021

Research

Treatment of Latent Tuberculosis Infection-An Update.

Clinics in chest medicine, 2019

Research

Updates in the Treatment of Active and Latent Tuberculosis.

Seminars in respiratory and critical care medicine, 2018

Related Questions

What are the chances of developing active Tuberculosis (TB) after 25 years of Latent Tuberculosis Infection (LTBI) with a small lung granuloma and no history of active disease?
What is the treatment for tuberculosis (TB) diagnosed by Interferon-Gamma Release Assay (IGRA)?
Does the TB Gold test become negative after treatment of latent tuberculosis infection?
Is a mask required for latent tuberculosis (TB)?
Is latent tuberculosis (TB) infectious?
What is the diagnosis for a patient with elevated parathyroid hormone (PTH) levels, vitamin D deficiency, hypercalcemia, and impaired renal function, as indicated by an estimated glomerular filtration rate (eGFR) of 63?
What is the workup for elevated parathyroid hormone (PTH) levels, low vitamin D, hypercalcemia, and impaired renal function with an estimated glomerular filtration rate (eGFR) of 63?
What is the relationship between skin necrosis and Continuous Renal Replacement Therapy (CRRT)?
What is the concern with Patient CK's current regimen of daptomycin (cubicin) 1000 mg per day, given her last creatine kinase (CK) level was 491 and her last reading on 4/16 was 67, indicating impaired renal function or other potential issues?
Is Cephalexin (Keflex) effective for treating Urinary Tract Infections (UTI)?
What is the survival rate for a patient with adenocarcinoma, classified as stage IIB (Clinical stage), with a diagnosis of non-small cell lung cancer (NSCLC) in the right lower lobe, peripheral, cT2aN1M0 (Tumor size 2a, Node involvement N1, Metastasis M0)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.